ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY)

Historical Holders from Q4 2020 to Q3 2025

Symbol
SPRY on Nasdaq
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
98,567,360
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
83,632,743
Holdings value
$840,434,931
% of all portfolios
0.001%
Number of holders
187
Number of buys
111
Number of sells
-85
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 11.1% $111,050,917 10,940,977 RA Capital Management, L.P. 29 Sep 2025
Flynn James E 7.75% -11.6% $134,624,739 -$18,102,531 7,610,217 -11.9% Deerfield Management Company, L.P. 30 Jul 2025

Institutional Holders of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 83,632,743 $840,434,931 -$93,310,803 $10.05 187
2025 Q2 84,521,210 $1,475,027,148 +$149,943,852 $17.45 185
2025 Q1 76,226,291 $958,937,759 +$63,838,841 $12.58 182
2024 Q4 71,304,827 $752,320,202 +$68,074,351 $10.55 163
2024 Q3 63,765,651 $925,913,322 +$31,092,478 $14.5 148
2024 Q2 62,590,275 $533,041,807 +$21,909,612 $8.51 112
2024 Q1 59,892,345 $612,088,771 -$16,199,586 $10.22 113
2023 Q4 65,423,068 $358,517,051 -$2,784,476 $5.48 99
2023 Q3 66,524,840 $251,464,826 +$38,754,815 $3.78 94
2023 Q2 55,071,412 $368,976,724 +$11,246,123 $6.7 92
2023 Q1 53,405,274 $347,669,060 +$19,586,591 $6.51 88
2022 Q4 50,164,476 $427,856,540 +$173,112,031 $8.53 72
2022 Q3 30,422,972 $160,377,408 +$24,492,078 $5.28 58
2022 Q2 26,061,019 $110,514,000 -$387,734 $4.24 60
2022 Q1 26,983,988 $94,707,000 -$19,556,342 $3.51 66
2021 Q4 30,103,833 $200,460,000 -$13,223,479 $6.66 71
2021 Q3 28,894,700 $288,363,500 -$42,490,899 $9.98 73
2021 Q2 27,989,545 $864,603,729 +$5,243,899 $30.89 74
2021 Q1 27,691,694 $1,205,836,321 +$139,058,596 $43.63 67
2020 Q4 24,444,347 $1,127,544,026 +$1,117,084,030 $46.34 61